文献速递遗传性与小管间质肾病

白藜芦醇通过减轻核因子κB诱导的炎症延缓多囊肾病进展

Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
PubMed 文献 · Nephrol Dial Transplant · 2016-04-19

本研究在Han:SPRD(Cy/+)大鼠、人多囊肾病细胞、三维囊肿模型和斑马鱼中观察白藜芦醇的抗炎作用及机制。白藜芦醇降低Cy/+大鼠血尿素氮、肌酐、肾脏重量比和囊肿体积密度,减少增殖与巨噬细胞浸润,并抑制NF-κB活性及MCP-1、TNF-α、CFB表达。作者认为靶向炎症可能成为多囊肾病治疗的新策略。

要点

  • 白藜芦醇降低Cy/+大鼠血尿素氮20%、肌酐24%、双肾/体重比15%、囊肿体积密度24%。
  • 白藜芦醇使囊性肾增殖指数降低40%、巨噬细胞浸润指数降低43%。
  • 白藜芦醇与NF-κB抑制剂QNZ在多种模型中抑制囊肿形成和炎症因子表达。

核心结论

  • NF-κB信号通路在多囊肾组织中被激活并部分参与炎症。
  • 通过白藜芦醇靶向炎症可能成为未来多囊肾病治疗的新策略。

研究设计与样本

  • 雄性Han:SPRD(Cy/+)多囊肾大鼠给予200 mg/kg/天白藜芦醇或溶媒灌胃5周。
  • 研究使用人常染色体显性多囊肾病细胞、三维Madin-Darby犬肾细胞和斑马鱼,给予不同浓度白藜芦醇或NF-κB抑制剂QNZ。

主要发现

  • 白藜芦醇使Cy/+大鼠血尿素氮降低20%、肌酐降低24%、双肾/体重比降低15%、囊肿体积密度降低24%。
  • 白藜芦醇使囊性肾增殖指数降低40%、巨噬细胞浸润指数降低43%。
  • 白藜芦醇降低Cy/+大鼠肾脏MCP-1、TNF-α和CFB水平,同时NF-κB(p50/p65)活性下降。
  • 在人多囊肾病细胞中,白藜芦醇和QNZ抑制MCP-1、TNF-α和CFB表达并降低NF-κB活性。
  • NF-κB阻断可减弱白藜芦醇对炎症因子产生的抑制作用,白藜芦醇或QNZ抑制三维囊肿和斑马鱼模型中的囊肿形成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation plays an important role in polycystic kidney disease (PKD). The current study aimed to examine the efficacy of the anti-inflammatory compound resveratrol in PKD and to investigate its underlying mechanism of action. METHODS: Male Han:SPRD (Cy/+) rats with PKD were treated with 200 mg/kg/day resveratrol or vehicle by gavage for 5 weeks. Human autosomal dominant (AD) PKD cells, three-dimensional (3D) Madin-Darby canine kidney cells and zebrafish were treated with various concentrations of resveratrol or the nuclear factor κB (NF-κB) inhibitor QNZ. RESULTS: Resveratrol treatment reduced blood urea nitrogen levels and creatinine levels by 20 and 24%, respectively, and decreased two-kidney/total body weight ratio by 15% and cyst volume density by 24% in Cy/+ rats. The proliferation index and the macrophage infiltration index were reduced by 40 and 43%, respectively, in resveratrol-treated cystic kidneys. Resveratrol reduced the levels of the pro-inflammatory factors monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α) and complement factor B (CFB) in Cy/+ rat kidneys in parallel with the decreased activity of NF-κB (p50/p65). The activation of NF-κB and its correlation with pro-inflammatory factor expression were confirmed in human ADPKD cells and kidney tissues. Resveratrol and QNZ inhibited the expression of MCP-1, TNF-α and CFB and reduced NF-κB activity in ADPKD cells. Moreover, NF-κB blockage minimized the inhibition of inflammatory factor production by resveratrol treatment. Furthermore, resveratrol or QNZ inhibited cyst formation in the 3D cyst and zebrafish models. CONCLUSIONS: The NF-κB signaling pathway is activated and partly responsible for inflammation in polycystic kidney tissues. Targeting inflammation through resveratrol could be a new strategy for PKD treatment in the future.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wu M, Gu J, Mei S, et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrol Dial Transplant. 2016. PMID: 27190325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。